A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
about
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Combination therapy for the treatment of Crohn's disease.Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to InfliximabThe relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel diseaseInfliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn DiseaseAntibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBDPharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Utilisation of anti-TNF levels in a UK tertiary IBD centre.Use of anti-TNF drug levels to optimise patient management.Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.Immunogenicity of biologics in inflammatory bowel disease.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease.Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience.Efficacy of vedolizumab in fistulising Crohn's disease: Exploratory analyses of data from GEMINI 2.
P2860
Q27021612-8C8D3CFA-322C-4234-AB6A-AACA76112752Q35714202-3364C3C3-A4EB-4E44-B8E7-0493BD131C9AQ35869305-F2F1E488-9FD3-4DF0-9473-E929446D0CA3Q36150080-385A6596-C117-4A4A-999F-5A5368737987Q36330198-56FA2DFD-A972-4B78-A6BC-48040614B420Q36828605-96E317C4-DA77-4831-B2FD-A04995F25542Q37613845-1163A1CD-F3A6-4621-B041-B1B40A75131DQ38364461-2DFBC5D0-1924-4AD9-86FF-B72E7AF4367CQ38365049-7DCDA37F-37E2-45B5-B542-5FE1C41911D1Q38365848-0844805A-9353-437C-B5CD-114BA734283FQ38435506-3141A786-F062-4C3C-9CA4-ABB0F30C1B1FQ38462602-412FB54B-011B-4050-9B72-A65433B8F2DEQ38564877-CF6987C8-774E-4CE6-9A1A-DE758F62EA8CQ38608944-2193B5C3-6FA2-4F15-8881-A8EEE30468A4Q38608951-76B4B9D9-E1DC-46C3-B20C-E34B388FAB77Q38628770-0B9B4E87-5E94-471B-9E7E-7ECD3580B3DAQ38673082-38CB4D22-7A48-4B32-866F-2D7275D733CFQ38695300-9E19C6BB-C2C5-48E6-94AC-7ADBD49F75A5Q38719570-127CBD09-51AC-42F4-B9AF-7062AB8CA137Q38789642-B162786F-ABA5-4383-99CD-C4D66B1F8282Q38822920-17E049AF-8501-4B3E-9B72-BA780C0CC32BQ38826447-E05C3951-F159-4B44-BBF6-BFD9B3A21F8BQ38856947-776A1185-2DA1-46C5-B304-897BE5BC0186Q38923616-C9D2B1B9-30B2-4227-A2E7-86451A66DDF2Q39030608-7894F484-55CC-429F-8F95-B093E73A5AC4Q39371316-6EC0A988-5946-427F-BFB7-87C6BF087E2FQ41237023-9289C7FA-D5FE-4595-922A-6C1D0800F800Q41451555-4E6CAC0A-33AD-4E5D-B8BC-464B778108A7Q44522018-D06CBBA9-D928-4D42-A078-702BD1BD4192Q46493947-AEA84B2D-1561-43D7-B0C1-C61F130FFB70Q47698698-C13ED81F-682E-4A2C-A135-016E726A69E6Q47736134-728552DC-BAE0-40A7-B729-A576C51205AEQ47747881-7D67A98B-E9D6-4A84-A158-F443D02858FBQ47805665-E923252E-0C1E-4640-B41E-AA2B03448156Q48327816-7B94A4FC-A377-4898-9FEE-E42A983F03FEQ49404676-720841A8-5195-48C8-87C1-06191AD6FE50Q50065301-CEFCDEC0-99A2-4EE3-B3A3-F6807014A1C3Q50469584-2A756A66-37ED-43B7-BBAC-90E6955BE981Q51584215-E57DAD8A-5DC0-47A2-8BF0-12A32D3C4901Q51748809-DF8CBE67-E159-4D62-864E-759246A7085F
P2860
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A prospective cohort study to ...... with luminal Crohn's disease.
@en
type
label
A prospective cohort study to ...... with luminal Crohn's disease.
@en
prefLabel
A prospective cohort study to ...... with luminal Crohn's disease.
@en
P2093
P2860
P356
P1476
A prospective cohort study to ...... with luminal Crohn's disease.
@en
P2093
B G Levesque
G R Greenberg
J Ducharme
L M Shackelton
S Hauenstein
P2860
P304
P356
10.1111/APT.12733
P407
P577
2014-04-01T00:00:00Z